Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targacept’s AstraZeneca Deal Down, Not Out

This article was originally published in The Pink Sheet Daily

Executive Summary

First Alzheimer’s Phase III results are not great, but partner wants to see more before deciding.

You may also be interested in...



Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors

Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.

Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors

Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.

Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets

Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug

Related Content

Topics

UsernamePublicRestriction

Register

PS068353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel